肿瘤型M2丙酮酸激酶对肺癌诊断价值的Meta分析

Meta-analysis of diagnostic value of tumor M2 pyruvate kinase for lung cancer

目的系统评价肿瘤型M2丙酮酸激酶对肺癌的诊断价值。方法全面检索Medline、Embase、中国期刊网、万方、维普等数据库,收集利用肿瘤型M2丙酮酸激酶诊断肺癌的文献。利用QUADAS评分工具评价纳入文献的质量。采用Meta-Disc 1.4软件计算合并敏感度、特异度、阳性似然比、阴性似然比、诊断优势比等指标,绘制汇总受试者工作特征(SROC)曲线,并计算其曲线下面积。结果共12篇文献1 408例研究对象纳入本次Meta分析,分析结果显示,肿瘤型M2丙酮酸激酶对肺癌的综合诊断价值为:敏感度为70%,特异度为92%,阳性似然比为8.15,阴性似然比为0.34,诊断优势比为26.16。SROC曲线下面积为0.91。结论肿瘤型M2丙酮酸激酶对肺癌具有重要的诊断价值,与其他肿瘤标志物物联合检测可提高诊断准确性。

Objective To determine the accuracy of tumor M2 pyruvate kinase（Tu M2-PK） in diagnosis of lung cancer.Methods After a systematic review of studies on evaluation of Tu M2-PK in the diagnosis of lung cancer in Medline,Embase,CNKI,WanFang Data and VIP Information,the methodological quality of each study was assessed by QUADAS.Sensitivity,specificity,positive likelihood ratio,negative likelihood ratio,diagnostic odds ratio were pooled by employing Meta-Disc 1.4 software.Summary receiver operating characteristic（SROC） curve was made and the area under the curve（AUC） was calculated.Results 12 studies with 1 408 samples were included in the present meta-analysis.The summary estimates for Tu M2-PK in diagnosis of lung cancer showed that the sensitivity was 70%,specificity was 92%,positive likelihood ratio was 8.15,negative likelihood ratio was 0.34,diagnostic odds ratio was 26.16,and the AUC of SROC was 0.91.Conclusion Tu M2-PK plays an important role in the diagnosis of lung cancer,the combination of Tu M2-PK and other tumor biomarkers increase the diagnostic accuracy.